SAM
NBIX icon

SEB Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

SEB Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8M Buy
176,754
+97,177
+122% +$14.4M 0.11% 164
2026
Q1 		$10.5M Buy
+79,577
New +$10.6M 0.04% 308

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

SEB Asset Management's NBIX Position: Q2 2026 in Review

SEB Asset Management increased its Neurocrine Biosciences (NBIX) stake by 122% in Q2 2026, buying an estimated $14.4M and bringing the position to 176,754 shares worth $29.8M. The position accounts for 0.11% of the portfolio, ranked #164.

SEB Asset Management first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SEB Asset Management held 176,754 shares of Neurocrine Biosciences worth $29.8M as of Q2 2026.
  • SEB Asset Management bought 97,177 Neurocrine Biosciences shares in Q2 2026, an estimated $14.4M.
  • Neurocrine Biosciences made up 0.11% of SEB Asset Management's portfolio in Q2 2026, its #164 holding.
  • SEB Asset Management first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.